Arterial Network unveiled the 2026 Top 100 Future Healthcare Enterprise Rankings recently. Boasting outstanding technological prowess and sustained innovation strength in indigenous original gene sequencing technology, Cygnus Biosciences has once again secured a spot on the Top 100 List of Innovative Medical Devices & Intelligent Manufacturing in China.
Launched jointly by VB100, Arterial Network and Eggshell Research Institute in 2015, the Top 100 Future Healthcare Enterprises ranking stands as China’s pioneering authoritative selection focusing on unlisted innovative medical enterprises. Designed to tap into innovative Chinese forces steering the future of healthcare, the ranking fuels transformation and upgrading of the medical industry, and has evolved into a vital benchmark for tracking innovation trends across the healthcare sector.
A national high-tech enterprise, Cygnus Biosciences dedicates itself to independent research and development of next-generation sequencing technologies and core instruments. Its proprietary LumoSeq technology enables more precise, efficient and stable decoding of genetic information. The company has developed two fully self-developed gene sequencing product lines, the S Series and P Series, with complete independent intellectual property rights.
The S Series comprises GS100 and GS200 sequencing systems. Both models have obtained CE market approval. The P Series covers the GP1000 sequencing system and GP1000X sequencing system, with a single-run data throughput ranging from 0.3 to 40 Tb.
Amid rapid technological iteration and booming innovation achievements in gene sequencing, Cygnus Biosciences’ repeated inclusion in the ranking stems from its self-reliant core technologies, robust R&D investment and comprehensive industrial layout. The honor fully validates the firm’s technological strength, innovation capacity and industrialization accomplishments, and underscores its pivotal role in advancing domestic gene sequencing localization and safeguarding public health.
Going forward, Cygnus Biosciences will further deepen its footprint in gene sequencing, uphold independent innovation, and accelerate technological iteration and product upgrading. The company will also expand domestic and global market presence, strengthen collaboration across the industrial chain, and foster an open and win-win industrial ecosystem. Deciphering the inherent order of life serves as a core driving force for scientific advancement and social progress. Cygnus Biosciences aims to cooperate with global partners to explore broader and deeper prospects for biotechnology development.
